N
Google TrendCOVENTRY VS NEWCASTLE (2000+) — Premier League LIVE: Coventry City vs Newcastle United - build-up, team news, score, text commentary & match stats
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:coventry vs newcastle2000+levante - sevilla2000+servicio de control de inmigración y aduanas1000+indigo girls500+afc champions league200+what's on netflix200+essie fall nail polish trends 2026200+champions league schedule500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "First-in-Human Randomized" (30 stories)

Top Headline Story

Inhaled siRNA therapy targeting RAGE for pulmonary inflammation: a first-in-human randomized trial
Lead StoryNaturegeneral
Sep 9

Inhaled siRNA therapy targeting RAGE for pulmonary inflammation: a first-in-human randomized trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5wWkszZ0JTa1ZHTEtFb0hHNHhOcHo1TFpXOHViNHFGckxBd01XMkkwY0FLcjVRZ081NER4OXJId3NpdWlnT0R1WW1vaENNX3NqVEtfOU1vYmRzX0ZYd0pn?oc=5" target="_blank">Inhaled siRNA therapy targeting RAGE for pulmonary inflammation: a first-in-human randomized trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
2000+31m ago

coventry vs newcastle

Premier League LIVE: Coventry City vs Newcastle United - build-up, team news, score, text commentary & match stats

Filter stories
2000+31m ago

levante - sevilla

Levante - Sevilla en directo

Filter stories
1000+31m ago

servicio de control de inmigración y aduanas

"La cosa se está poniendo tensa": manifestantes se enfrentan a agentes migratorios en Oregon

Filter stories
500+31m ago

indigo girls

Indigo Girls cancel show after tour bus driver dies in highway crash

Filter stories

Search Results for "First-in-Human Randomized"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
First in Human Long-Acting Gene Silencing Therapy Significantly Lowers Heart Disease Risk Marker with One Injection
Cleveland Clinicgeneral

First in Human Long-Acting Gene Silencing Therapy Significantly Lowers Heart Disease Risk Marker with One Injection

<a href="https://news.google.com/rss/articles/CBMi9gFBVV95cUxQcmliWElpWDZZTkIyYUExNGdHN0N6UlFiOHhHX01YalliTnlkZXhkZ3JrM19sZXkzRmlfOGVNVnNxc2M5a0YwMTU3OHlBZFhrX015dDM5OWdoWTFuWGw2RnFuZ2NTZ3NJVnMyOEg0ckpHaF9za2tDLUNxV1B1SlZzX0xYOUhtaGhGLVhsYzVBYXFkZUUwWF9MT0lpYmI2WDk2ZG1VRWlVVHpiMC1FcU1JVlgwblpweTQzZll6Z1lpMElnV0ctQXhtdVNkaFkzaHBfMk1YYnVYeHZaUDloVDRlUFQ1VUpfMEFESkpHbEFmNUctOUkxQ0E?oc=5" target="_blank">First in Human Long-Acting Gene Silencing Therapy Significantly Lowers Heart Disease Risk Marker with One Injection</a>  <font color="#6f6f6f">Cleveland Clinic</font>

Read Full StoryMore like this
First-in-Human Randomized Controlled Pilot Trial of a Maxillofacial Drug Delivery Platform for Low-Dose Systemic Delivery
Cureusgeneral

First-in-Human Randomized Controlled Pilot Trial of a Maxillofacial Drug Delivery Platform for Low-Dose Systemic Delivery

<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxQUGtHWHMyTW55M0RZUUFWRXRWbUR6U0Y1LS1hVkRXcmZTTlU3d3hFRGNTLUhsWUVxaDZzRzlqQ1REVmpYamlYWjlwakd5ZzE4R19hRkhkaFhaUHVNSFJ3X1BnU2l6VFk4QWg3MVdDeEVneFBhOEVBVlJ4UHRZZmt5dU8xSlNadEE2SkFmdDZFNEY1TVVmbW8yTi1sMnhiWGxURXdrODVMOVdHYzhTQmRsVElhenVvdGlaMGdlUTJLVzczbGk3U0N1RjNlWEF0U01kQ1Y4SzVCQi0ySXVYZC1Rb2J2UmUxZlJTQW1uOUxqWGRyUQ?oc=5" target="_blank">First-in-Human Randomized Controlled Pilot Trial of a Maxillofacial Drug Delivery Platform for Low-Dose Systemic Delivery</a>  <font color="#6f6f6f">Cureus</font>

Read Full StoryMore like this
First in Human Long-Acting Gene Silencing Therapy Significantly Lowers Heart Disease Risk Marker with One Injection
Florida Hospital News and Healthcare Reportgeneral

First in Human Long-Acting Gene Silencing Therapy Significantly Lowers Heart Disease Risk Marker with One Injection

<a href="https://news.google.com/rss/articles/CBMi9wFBVV95cUxOUGtHU3R4em9SUFB2Vl9NN0FZOVgxd1NaV253bXM1OGFGbTAxaDF0ay1OaVFDWVJETjYyX180R3FPbjdlUmh0UVVPelkwaXNMUGhVMm5uRFZYYV9fMkx0bkVFa053MW0wMXR6OGFIZWdRcmk2bXhsc3dBalR0cXlNUEdpaVFNVEFYR0dkSzBJcG04a1J0SlNLRmw2QzJFUmZwVkQ5WTVTWTJCc0pPQ0JoRHVNTWxTWkk5dkU2OEtKLTRIdmtKY2xkVGx1ZFhvVHJVMjNnOGxjX1FZa3hQREdEcXFsd1ZjU3ZQQlh2RUVnYUJPMVhvc2Q4?oc=5" target="_blank">First in Human Long-Acting Gene Silencing Therapy Significantly Lowers Heart Disease Risk Marker with One Injection</a>  <font color="#6f6f6f">Florida Hospital News and Healthcare Report</font>

Read Full StoryMore like this
Chikungunya therapy shows promise in first-in-human study
Healioworld

Chikungunya therapy shows promise in first-in-human study

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxNZWlRcllvUmdCTWNxUFJ0MG5RWTY5ZmdWTVRPVVU0MXR2T2RVV1Y5dlVjeS04cFhseE1lS1pLQ1Blc0JFb0oyYm5iZm5WSWNRdk5mcG1md3ZoV3g2SXVhcmdtVWU5WURPQ1VkMDU2SmNvNU9kQzFmQ0tiaUt2d3owM3BNUVVtM2Utd2FOdzE5emhSeWdzV3BRZ0hLY3pDWkFKaGJtaWVzS1dvVk9ncUdtdg?oc=5" target="_blank">Chikungunya therapy shows promise in first-in-human study</a>  <font color="#6f6f6f">Healio</font>

Read Full StoryMore like this
BioNTech Launches mRNA HIV Vaccine Trial
AllScitech

BioNTech Launches mRNA HIV Vaccine Trial

<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxQOVljX3QxQjI4ZG1MMmlQSmxaaFhqRDR2bTBYUWsyTzZFWDZNMGs4bDlzcWxEMUQ4bFdaZkV2ZzEzUFRnXzFYc2RsbEJ0SG43bmNDbUMwNXJaMmRVYzFOdzRHQklKSWtQTVlfc1FSTHItUzRZY0FYLV9tU1FBMndJZ0xJaXNlNUFxNDlkOGxiNHZPRFZtQ29wNW9ZVE9SUlBtMkt0cUN4d1BZWFhVcmo5Wlg5V3g4M2c1LWY3VkM3b1hpaXB1RE0tdTNPQlpTSmM1U1NLeEtDLTNwZw?oc=5" target="_blank">BioNTech Launches mRNA HIV Vaccine Trial</a>  <font color="#6f6f6f">AllSci</font>

Read Full StoryMore like this
BIIB091 First-in-Human Safety, Tolerability, Pharmacokinetics, and Pha | DDDT
Dove Medical Press Ltdgeneral

BIIB091 First-in-Human Safety, Tolerability, Pharmacokinetics, and Pha | DDDT

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxPOE5MRm03dkNaRmI4NDA0Y016ZVF1YUdBRUV0dGlqYW9SMWpfaWFsY1J1MVl2QkNxSXc3QTdyQnppcC05bVJmYlhCanRBVFl2R2FxN1JpeXVZcEN3YzVEWGNPODRSMnVJRjBLTWlXcVJhaHZwWXh4dExBbHJhSG5mdThMNUFqSmViRUpuaGhXckFrZ19GM1dJdVZPbW1SVEVOYkNSeU1YbWUyUTY2ekQzTlZxc1c3dDQyRHBycWVxN0Y3NzBrNWVwWm1aVlo?oc=5" target="_blank">BIIB091 First-in-Human Safety, Tolerability, Pharmacokinetics, and Pha | DDDT</a>  <font color="#6f6f6f">Dove Medical Press Ltd</font>

Read Full StoryMore like this
Retro Bio commences first-in-human trial
Longevity.Technologygeneral

Retro Bio commences first-in-human trial

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxONktCd2pzNlpaSmcxZVN6RkdKYmxXc01HNlFvUnR2aExHMUx3Q1Z2LThGV3MxYTlnUXVwVFBXaXhQWDMzZXk2Ny1lbzltb3lzcVN1MWRlYnZMcnVlNjcxZTh3U3k5MGhwNjIxb0ljVDlfV2tiVkFXSmRMWUlld3AtYw?oc=5" target="_blank">Retro Bio commences first-in-human trial</a>  <font color="#6f6f6f">Longevity.Technology</font>

Read Full StoryMore like this
Marea Therapeutics Presents Phase 1 Data Supporting Potential Best-in-Disease Profile of MAR002 for the Treatment of Acromegaly at ENDO 2026
BioSpacegeneral

Marea Therapeutics Presents Phase 1 Data Supporting Potential Best-in-Disease Profile of MAR002 for the Treatment of Acromegaly at ENDO 2026

<a href="https://news.google.com/rss/articles/CBMijAJBVV95cUxNUzVCSzhqVlpHdzF1eG9ZNy00ejM3dVd4cnU2RmR2eUlFMUQ1NUF1LTBXZjRYTXZDWjc2bnJ1b2dISFhzZHJBcWVjd3NwQWRmYjVENFJDalBTaV9Kc3RMaThLdFc1bGt4aFhvbE00NDlGdXRjWlF6UmxwUllqSzFWUEhTZHA1YkFtQkRDMFJYTnhHbWxBY1FUaWpnWFlDdklVa1FCLVByN1YySldrcEliaWpXSVRfZ1luVmdKSVpjQS1VTHFRMmhQRjNJRm1iak05eWtyUVBGekIyT0dlNGJ5RmdjaWtBRk9sQjVKVVdBc19tdmRLMDZlOGkyd2xxM0VMdWZHa25uZXJaTnZB?oc=5" target="_blank">Marea Therapeutics Presents Phase 1 Data Supporting Potential Best-in-Disease Profile of MAR002 for the Treatment of Acromegaly at ENDO 2026</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
Insilico Medicine to Present 3 Abstracts at the 2026 Crohn’s & Colitis Congress Highlighting Clinical, Preclinical Safety, and Efficacy Data for ISM5411, a Novel Gut-Restricted PHD1/2 Inhibitor
Insilico Medicinegeneral

Insilico Medicine to Present 3 Abstracts at the 2026 Crohn’s & Colitis Congress Highlighting Clinical, Preclinical Safety, and Efficacy Data for ISM5411, a Novel Gut-Restricted PHD1/2 Inhibitor

<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxPR05fNmstUVFGOE84VTVNdnRrU3FqRkNtWGhNVkM0RVlYbEFaSFB5cVlsN2RWbF9jNFJiUmN2dG9EaGR1OXAwb2llQXFlNTZqN2JGamVYOEt5cUJibG5YQUkwZ3R4R2IzSEZxbWo3NmJyYmd5Rlg1bTRhWl9mRTY0UTBNTQ?oc=5" target="_blank">Insilico Medicine to Present 3 Abstracts at the 2026 Crohn’s & Colitis Congress Highlighting Clinical, Preclinical Safety, and Efficacy Data for ISM5411, a Novel Gut-Restricted PHD1/2 Inhibitor</a>  <font color="#6f6f6f">Insilico Medicine</font>

Read Full StoryMore like this
iVeena Delivery Systems Announces First Patient Dosed in Phase 1 Study of IVMED-85 in Healthy Adult Volunteers
Business Wirescience

iVeena Delivery Systems Announces First Patient Dosed in Phase 1 Study of IVMED-85 in Healthy Adult Volunteers

<a href="https://news.google.com/rss/articles/CBMi-wFBVV95cUxPMUhpdnYzMVBCaHZrUWxlVzZmUThGcnB5OGU0eEpKeXhCTkVaNU13S3phV0Rjd0hFTmYtTmxtc2pNaHRuMzlxaHFOb21BVVJRWnAxV1ZTNVlSblZLMU55dDdEY3Vac0dYcDlhVXZMVlVJVWZWZnZuWnVJMGY5emRtVVhLaC1MS0RpVndRTlR0V2tzbWs0Tmkza2NkbE1LUW5vSDVrc05hcXpKOXY4VDAyMVAtWVlYY0l6VWx0b290UDc4NllBX2dSTHZkbGtXYVFEM3lYRXYwUjZnMGpFMUtyelNySHU1RUpBWFd0SldWSW9ZVjVqSHI0cjhRQQ?oc=5" target="_blank">iVeena Delivery Systems Announces First Patient Dosed in Phase 1 Study of IVMED-85 in Healthy Adult Volunteers</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
AdJane Reports First Clinical Validation of its OMV Vaccine Platform Inducing Mucosal Immunity in Humans
GlobeNewswireworld

AdJane Reports First Clinical Validation of its OMV Vaccine Platform Inducing Mucosal Immunity in Humans

<a href="https://news.google.com/rss/articles/CBMihwJBVV95cUxNRlpNdkpwaDhOckVndEtkdlJWWERBYVhDME9JcXFIT05PcnctYjdUWmRzUFNmcDl2U0lvckNncXBvWExpS1BYUUdnWjJzUG1PeWNDNG12ZndWSWlhV0JpOVQ2anE5N1B0Y2lNLUZlZjMxa3Bkc01KTnc1SlYyYzhTSEdrZllNMzhsQ090ZllGUjN0NHVVdlZNUFNpX2E5NXRzS3ZZcnl3ZjZreTZkdnRIdVVZQzBFNmkza0x1cU85VU1aSFFGWlMtMmRJUW1PM3YxV2Q4UVdoY3FjdDNid0xzUlN4T19UV1ZQNlBTR292bUF0bmlRdzdxelJnTGplN09UOWlKQmRPOA?oc=5" target="_blank">AdJane Reports First Clinical Validation of its OMV Vaccine Platform Inducing Mucosal Immunity in Humans</a>  <font color="#6f6f6f">GlobeNewswire</font>

Read Full StoryMore like this
Acta Pharma Advances GSM-779690T Phase I Trial
AllScigeneral

Acta Pharma Advances GSM-779690T Phase I Trial

<a href="https://news.google.com/rss/articles/CBMijgJBVV95cUxQdG5ROHhJRFdubDFHVE1HYXhwSEkwb3JQS3NOalctXzh3eXlsQUV4Snp0eHdIU19XbnE1OFVaM0JXcGhlc3lsSnQ0OWpQbHdwVlFldWY1ck5uNkVCTG9aeGpseFZqMGRSeW1tMXhldUJEQTdMYV9WUk9LcXFRUmZYRXVkTThISkg2eVRsSkd4d0RfejhvUjgtSEVaWFlMTXJBYWVZeVRfQXBhUzFSZHNQSENhSDUySW50UW1tYVIzSFVnYzM3VkMxYjg1MHFJZ3NkMl9VRzVKQ1BCQVpWSlFGeVdIYndMU1NPWnF0blhRd0V6WTQzYU0yTVJ5ckhVdDRfbTUxcWx3N0Zua24zZXc?oc=5" target="_blank">Acta Pharma Advances GSM-779690T Phase I Trial</a>  <font color="#6f6f6f">AllSci</font>

Read Full StoryMore like this
Blood Pressure Lowering Effects of a Novel Long-Acting NPR1 Agonist, XXB750, in Healthy Participants: A Randomized, First-in-Human Clinical Study
American Heart Association Journalsscience

Blood Pressure Lowering Effects of a Novel Long-Acting NPR1 Agonist, XXB750, in Healthy Participants: A Randomized, First-in-Human Clinical Study

<a href="https://news.google.com/rss/articles/CBMic0FVX3lxTE94QVJiNXJNYnM2S2V6eVpjX3F2alN1MS1qbVFya3Z1WWphMF9rWkNwQ25rSDdnMDB1aDV0UkM4S1ZrcUVJYjZKekNaQWpab0hHdUNaaklWVFNpZVF6cEg2dTB4Z2NKZTVWR2tIZWNkMElsd2c?oc=5" target="_blank">Blood Pressure Lowering Effects of a Novel Long-Acting NPR1 Agonist, XXB750, in Healthy Participants: A Randomized, First-in-Human Clinical Study</a>  <font color="#6f6f6f">American Heart Association Journals</font>

Read Full StoryMore like this
A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults
Wiley & Sonsscience

A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults

<a href="https://news.google.com/rss/articles/CBMia0FVX3lxTE9mb05Gd2NMUVM0dkZReHlXWW8zY1BHVkxybUU4NlRSWEtiRDdGN1RRVXNJVzZ1S0EycVR4U3dYSURGY0RSc0tFMEx2dXBGcDY0eDI2YTZYLXlXaEl6dmZLaWR0RlVaSmxBWW9v?oc=5" target="_blank">A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults</a>  <font color="#6f6f6f">Wiley & Sons</font>

Read Full StoryMore like this
Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study
The Manila Timesscience

Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study

<a href="https://news.google.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?oc=5" target="_blank">Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study</a>  <font color="#6f6f6f">The Manila Times</font>

Read Full StoryMore like this
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
The Lancetworld

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNTG5zbjBMOGd4NXlNWlFYX2FpMkY2elpyUXlJNG9Pb1FvaTV6WHJ2Z1llTS1ZX3ZEZk5FWHk0elE2MDVhaEFMMDdndEstUmhQWllUOGR4V3FGUWRLR2NIdjczNFZWZjFjWlZJbjJRSktGTnNtbkpPQjk3Ylh1N2VCZDMtektXNmJYU1R3?oc=5" target="_blank">Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial
Naturetech

Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFAtbUktMTJlZFpETTBMSnNlZ01RdXMzVmxhdzRJNXl2V1REbE4zN09CYmVlUGdlRWhPUkdQbGtFRkpCSDlZYjM3X0I1dVgydDRGR2ZWQUxTZ1J4VE9rcndF?oc=5" target="_blank">Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
2-Hydroxybenzylamine for Treatment of Atrial Fibrillation: A First-in-Human Clinical Pilot Trial
American Heart Association Journalsgeneral

2-Hydroxybenzylamine for Treatment of Atrial Fibrillation: A First-in-Human Clinical Pilot Trial

<a href="https://news.google.com/rss/articles/CBMiaEFVX3lxTE14ODdTLWtlcVc4QkQxWUIwWk8xcHNTSFgxSThjRU1aVFFRaWdlc3haZ05LSlJPc2lkWVdqaFBGSlB2TmZNOW1mNVFmOEZqWWtKaUJNRF9WdEpQTDlBNlk0UGJsOFBtczJ0?oc=5" target="_blank">2-Hydroxybenzylamine for Treatment of Atrial Fibrillation: A First-in-Human Clinical Pilot Trial</a>  <font color="#6f6f6f">American Heart Association Journals</font>

Read Full StoryMore like this
First-in-human robotic supermicrosurgery using a dedicated microsurgical robot for treating breast cancer-related lymphedema: a randomized pilot trial
Naturegeneral

First-in-human robotic supermicrosurgery using a dedicated microsurgical robot for treating breast cancer-related lymphedema: a randomized pilot trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1lX1dUeFpHUmktclFySnI0NVMtWXdXNzFWMVdrVzdSYzYwMkhPRWp6Qy1UaThTbWJUWldUWFFGOXFYYWNoTTFRbG1tY3ZWS0MyRjJlaG1BUEtnM2NqQTZ3?oc=5" target="_blank">First-in-human robotic supermicrosurgery using a dedicated microsurgical robot for treating breast cancer-related lymphedema: a randomized pilot trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Feasibility and safety of cellular therapy for in-utero repair of myelomeningocele (CuRe Trial): a first-in-human, phase 1, single-arm study
The Lancettech

Feasibility and safety of cellular therapy for in-utero repair of myelomeningocele (CuRe Trial): a first-in-human, phase 1, single-arm study

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxQYlpOSzNSWkdVc2czMW5GMHJETlV5MWVhNGJtTTczTGFGVkoyalVicG5lNzhLVFFMeTdsZWJuR3FIc0VlZXNoQlBTbGtnVVRhWHNiY3dJcjRxd01TNXRnS2FYdkhEdkJXVjRDanFocEZxWjZES3FIS3gzMmhtV1VINDNxdkJLNnZEYlZN?oc=5" target="_blank">Feasibility and safety of cellular therapy for in-utero repair of myelomeningocele (CuRe Trial): a first-in-human, phase 1, single-arm study</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Randomized phase I trial outcomes show safe and sustainable inhibition of classical and lectin complement pathways by empasiprubart
Naturetech

Randomized phase I trial outcomes show safe and sustainable inhibition of classical and lectin complement pathways by empasiprubart

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5PTjNmaHlhOHBJdFBPRkJpUUZPcWJuSnpVel8zUldFV2lvQWhmaS1lOWE0NktXQ3ZwXy1kOF9MWXdZVnBRS05PZ0M0SHE3S1FIQlBpdVE4VXZYLUY0RFcw?oc=5" target="_blank">Randomized phase I trial outcomes show safe and sustainable inhibition of classical and lectin complement pathways by empasiprubart</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
TIP103 Randomized Phase 3 Clinical Trial Evaluating Atirmociclib Plus Letrozole Versus a CDK4/6 Inhibitor Plus Letrozole as First-Line Treatment for Patients With HR+/HER2− Advanced/Metastatic Breast Cancer
CancerNetworkgeneral

TIP103 Randomized Phase 3 Clinical Trial Evaluating Atirmociclib Plus Letrozole Versus a CDK4/6 Inhibitor Plus Letrozole as First-Line Treatment for Patients With HR+/HER2− Advanced/Metastatic Breast Cancer

<a href="https://news.google.com/rss/articles/CBMi2wJBVV95cUxNU0o5Wk1meUl2S25pYkFDWXAzZTZHaGVjNWd4aFB0Tzg2THRQS2JkRzJmeHc4U3NSNS11dW8tSHZhOWZ5U0E5Ym9CSXpNQ1RncWhIbzExYmhHZGZxT2RGankxemJBQWJpRTBUOUNUdWRfdVV1VFpsQ1BPWjN1V25zcGszNWVMZ1BfMWplZnBXbWZUSHJhRURtbmFHTTRTNGtrYXJwcW5XbjJCaGdMd2VVUUhwV3ZURzQxY3F4NDdvS2s1emlGZ2ZQNmR2WXlyTkZyTjdOTWR5OVVCSU5qbUVwVVNZNHcydGJSV0N4R1NXNlN3cDdRZmdZNGJ3bUZnX2x6eW1VbG1WaVh4ZW5TS0MteUpOMUZIby1SUkJYekgxY2pycG9IZ0wzeXFxOENaTnE3dFhiTVZwQm9IUFJMSE5hY0NTV2toU1F0VkJaLWpHVlZTVC1MS1o2d0ZiWQ?oc=5" target="_blank">TIP103 Randomized Phase 3 Clinical Trial Evaluating Atirmociclib Plus Letrozole Versus a CDK4/6 Inhibitor Plus Letrozole as First-Line Treatment for Patients With HR+/HER2− Advanced/Metastatic Breast Cancer</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 rando
The Lancetgeneral

Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 rando

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxOV0d3UHFXUU5IaXUzZEpGTHhuemM4aFBYeF9STm45LTVkZDhsWUhsQUZDU0JRVjFMMUFHdk5CTjhMaVQwSFlDQno4Si1XV05OYi1JcFpaVml3U1Y2a2xnUDFXT0NDOXdqTlZzQ05naGtHYTJuTzFaUkNqaExYc3lzMEpjUWFMT3AxN3o0?oc=5" target="_blank">Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 rando</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial
The Lancetscience

Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxPQW1OaGxpblF0OW1RN3l6YnRUYjRzX1ZydG1EOVJHcXpoWC0zTXdDXzFGRG1LejE2Zkp5c25FcTQ1NmxOemlVWENLZG8zOWNBRTJxSW9jSjFGU21odUVRMklWSGVYRFU0QThFZXhsRk9ELVpyLTZab0YxazZqQnZ1N1BKckVreFR5SEEw?oc=5" target="_blank">Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial
Natureworld

Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9uWjBWMmtmT1FyMXNyN2U3Z2RtV0NmS0ZMaTducjlvMTJaX2s4X1JrWkVoZUhjMVJwLUFXeElvS1lhOHZSMnJmcjBQUWttZ0dXbHFUOE5wM3dKbWlMN2NR?oc=5" target="_blank">Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
First-in-Human Safety, Tolerability, and Pharmacokinetics of Single-Dose Kukoamine B Mesylate in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase I Study
SpringerMedizin.descience

First-in-Human Safety, Tolerability, and Pharmacokinetics of Single-Dose Kukoamine B Mesylate in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase I Study

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQSHVueVg0S2ZaMkpEby1OVnc5SHViRm4zQW9TeWFEd1JzLUN5WUlwZXhxWE5SMnpLOUZVaGxVS0lPU3ZvNzN4MExzR0Z2Y18wbDVnemVyWVg5RkcxZmpfeGwtbjRvOElVQllTVjNlN19zX2pyamxYaWZqdEpIbWtLTWJVcE80NVNmRXhRbzZpSEd0Q3lhVkdQZndVUF95NWo4MzkzcGdFMA?oc=5" target="_blank">First-in-Human Safety, Tolerability, and Pharmacokinetics of Single-Dose Kukoamine B Mesylate in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase I Study</a>  <font color="#6f6f6f">SpringerMedizin.de</font>

Read Full StoryMore like this
GSK Launches Malaria Monoclonal Antibody Trial
AllSciworld

GSK Launches Malaria Monoclonal Antibody Trial

<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxQbUdYTkJRa0Y3WEZ4cWItN3dodVk5VDQ3MUFRblFyczZBX2paUUtIU2hkdUp2cVlwMElfNW9fMU9tX1RPdUhjYzlidWdEYWFJdThwcVJSS1FxeHlFRjlHck55NGJFRGhFV3VseHpJT3VjcGJrVElXaHNIVmVPYzA3RWQ5X0ZBS2NHcVFuMlVDenI3VC1JV3huWW1VU0pFWXJ5Q1hpaVJuckNneFM5Qlc0ZVI2Nk9tOEVmMzQ0a3lhZmE5N0wzTGV3dkNiRGpJNlh1enVLS3k4Mk1sd0R5S0JMSjVEcWg?oc=5" target="_blank">GSK Launches Malaria Monoclonal Antibody Trial</a>  <font color="#6f6f6f">AllSci</font>

Read Full StoryMore like this
Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial
The Lancetgeneral

Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxQbWVUbHk5YXdKcmpyYkllU0V4QkdnYXg0cUMta1l4dG5yYXAwa1l5TENmWGtKYnZoTEFyemFMQ0dFUk5Jb0tQZEJSZ0o0OE82YmhodlltNWFSQ1Frd3A1N1ctd25MQUJxTmdyN3F3WFUzeGZNS2tuSjNGTE1kR0lPR3VGeWtSZjkxRnpn?oc=5" target="_blank">Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Pharmacokinetics, safety, and tolerability of an oxfendazole tablet formulation: a phase 1, randomized, placebo-controlled trial in healthy African volunteers
ASM Journalsscience

Pharmacokinetics, safety, and tolerability of an oxfendazole tablet formulation: a phase 1, randomized, placebo-controlled trial in healthy African volunteers

<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE4zYk1CVTBvWkRqdk05QTdRTTFsZ3d4bjVDUnBsTVM4WmZycGo1c0VQckx5QU9WTzVEMEFEMGlLaHN6N19Zak5uemYySVdiZC1ZVkh4R0Zza1FRV01HSVE?oc=5" target="_blank">Pharmacokinetics, safety, and tolerability of an oxfendazole tablet formulation: a phase 1, randomized, placebo-controlled trial in healthy African volunteers</a>  <font color="#6f6f6f">ASM Journals</font>

Read Full StoryMore like this
"First-in-Human Randomized" — Live Google News Trends & Headlines